Abstract
Background Previous studies identified a strong linkage signal for non-syndromic persistent developmental stuttering on chromosome 3q13.2-3q13.33 in a large consanguineous family. To identify the causative genetic variant at this locus, including we performed further analysis, including whole exome, whole genome, and targeting Sanger sequencing.
Results We identified a homozygous rare c.2155G>A variant in ZBTB20 in individuals who stutter. This mutation encodes Isoleucine in place of a highly conserved Valine at amino acid position 719 in ZBTB20 that co-segregates (LOD = 4.23) with stuttering under a model of recessive inheritance with reduced penetrance in this family. Coding variants in this gene were significantly more frequent in a multiethnic cohort of unrelated individuals who stutter than in individuals in large population databases comprised of our normal control subjects and gnomAD database subjects matched for ethnicity. ZBTB20 encodes a zinc-finger transcription factor, and luciferase reporter constructs using genes known to be regulated by ZBTB20 showed that the Ile719 mutant form of the protein displays altered transcriptional regulation in vitro. Although homozygosity for mutations in ZBTB20 has not previously been observed, dominant mutations in ZBTB20 have been reported in Primrose syndrome, a rare Mendelian dominant disorder characterized by tall stature, developmental delay, dysgenesis of the corpus callosum, but generally not speech disorders. Clinical re-examination of the affected family members ten years after their original ascertainment revealed only some suggestive signs associated with Primrose syndrome.
Conclusions Our findings support variants in ZBTB20 as a cause of stuttering in a large family, and rarely in the wider population. Previous studies in mice have demonstrated that Zbtb20 is required for the development of astrocytes, a brain cell type previously implicated in an animal model of stuttering. Our findings support our hypothesis that astrocyte pathology is involved in this disorder. Our findings also broaden the medical genetic view of disorders of ZBTB20, and demonstrate that individuals carrying a homozygous mutation in this gene can be viable, and that they can primarily display persistent developmental stuttering.
Competing Interest Statement
Dennis Drayna serves on the Board of Directors of The Stuttering Foundation, a non-profit organization.
Funding Statement
This work was supported in part by the National Institute on Deafness and Other Communication Disorders (NIDCD) Intramural grant # Z01-DC-000047-19, the NIDCD Genomic and Computational Biology Core # Z1C-000086, and used the high performance computational capabilities of the Biowulf Linux Cluster at the National Institutes of Health, Bethesda, MD (http://biowulf.nih.gov). We thank Dr. Timothy Holy of Washington University St. Louis for support of TB, and The Stuttering Foundation, the National Stuttering Association, and Hollins Communications Research Institute, Roanoke, VA for assistance with subject recruitment.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Human subjects, including individuals from a consanguineous Pakistani family (PKST77) with the inclusion diagnosis of non-syndromic persistent stuttering were enrolled with written informed consent under National Institutes of Health protocol 97-DC-0057 (Genetic studies of stuttering), also reviewed and approved by the IRB of the National Centre of Excellence in Molecular Biology, University of the Punjab.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
Abbreviations used
- NIDCD
- National Institute on Deafness and Other Communication Disorders
- ZBTB20
- Zinc finger and BTB domain containing, 20
- NHLBI
- National Heart Lung and Blood Institute
- CED
- Communications Exome Database
- AFP
- Alpha feto protein
- IκBα
- Inhibitor of kB alpha
- GNPTAB
- N-acetylglucosamine-1-phosphate transferase subunits alpha and beta
- CRISPR-cas
- Clustered Regularly Interspaced Short Palindromic Repeats-Crispr-associated protein 9
- IRB
- Institutional Review Board
- NINDS
- National Institute of Neurological Diseases and Stroke
- PKSTR
- Pakistani stuttering affected individuals, unrelated
- PKNR
- Pakistani normally fluent controls, unrelated
- STCR
- Cameroonian stuttering affected individuals, unrelated
- RC
- Cameroonian normal control individuals, unrelated
- BRMII
- Brazilian stuttering affected individuals, unrelated
- BRCO
- Brazilian normally fluent control individuals, unrelated
- EMEM
- Eagle’s Minimum Essential Medium
- KI
- Knock-in
